Vicore Pharma Hits Early Enrollment Milestone in Key IPF Trial

Vicore Pharma Holding AB ( (SE:VICO) ) has shared an announcement.

Vicore Pharma has completed enrollment of more than 360 patients in its global Phase 2b ASPIRE trial of buloxibutid in idiopathic pulmonary fibrosis, hitting full recruitment earlier than expected across over 100 sites in 14 countries. The 52-week randomized, placebo-controlled study, which follows encouraging Phase 2a data, will evaluate the drug’s impact on forced vital capacity, the key regulatory endpoint in IPF.

The company plans to deliver topline ASPIRE results in mid-2027 and reports a cash runway extending into the second half of 2028, underpinning its ability to see the program through. Successful outcomes could strengthen Vicore’s position in the IPF market, where existing therapies offer only modest benefit and tolerability challenges, and would be closely watched by patients, clinicians, and investors seeking more effective treatment options in this high-unmet-need indication.

More about Vicore Pharma Holding AB

Vicore Pharma Holding AB is a Stockholm-listed clinical-stage biopharmaceutical company focused on respiratory and fibrotic diseases, particularly idiopathic pulmonary fibrosis. Its lead asset, buloxibutid, is a first-in-class oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designations in the United States and is being advanced through global mid-stage trials in IPF.

Average Trading Volume: 536,124

Technical Sentiment Signal: Sell

Current Market Cap: SEK2.91B

Learn more about VICO stock on TipRanks’ Stock Analysis page.